Global Phase 3 innovaTV301 Trial Results

Trial investigator Brian Slomovitz, MD, Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center, discusses results from the global, randomized, open-label Phase 3 innovaTV 301 trial, which showed treatment with tisotumab vedotin demonstrated statistically significant and clinically meaningful overall survival, progression-free survival, and objective response in recurrent or metastatic cervical cancer patients with disease progression on or after first-line therapy, compared with chemotherapy.

A specialist in clinical trial development, robotic surgery, sentinel lymph node evaluation, and immunotherapy, Dr. Brian Slomovitz is Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center in Miami Beach, Florida. He is also a Professor of Obstetrics and Gynecology at Florida International University.

Dr. Slomovitz is a member of the Board of Directors at the GOG Foundation and the Uterine Cancer Lead for GOG Partners. He is also the national or global principal investigator on a number of GOG Partners, NCI, and Alliance Foundation clinical trials. He authored more than 100 peer-reviewed articles and lectured extensively. In addition, Dr. Slomovitz has been recognized as a Top Doctor by Castle Connolly Medical for the past several years.

Dr. Slomovitz graduated from Rutgers University – New Jersey Medical School, and completed his residency at New York Presbyterian – Cornell Medical Center in 2002. At MD Anderson Cancer Center, he completed a fellowship in gynecologic oncology in 2006. He is board certified in both obstetrics and gynecology and gynecologic oncology.